预约演示
更新于：2025-04-13
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-04-13
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
79
项与 盐酸奥洛他定 相关的临床试验CTR20244886
盐酸奥洛他定鼻喷雾剂在健康受试者中的单中心、随机、开放、四周期、完全重复交叉试验设计、空腹给药的生物等效性研究
CTR20250136
盐酸奥洛他定片在健康受试者中空腹生物等效性研究
CTR20243907
盐酸奥洛他定片在健康人体空腹/餐后状态下的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
732
项与 盐酸奥洛他定 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
2025-03-16JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
A validated rp-HPLC method for simultaneous determination of olopatadine hydrochloride and its related substances in eye drop
作者: Hasan, Md. Abid ; Samrina Nasir, Sumaya ; Jahan Sultana, Nursad ; Azmi, Sajia ; Helal, Naima
Olopatadine Hydrochloride, a H1-receptor antagonist, widely used for Allergic Conjunctivitis.A HPLC method was created and validated for the quantification of olopatadine hydrochloride and its related substances in eye formulation in accordance with ICH standardsThe separation of olopatadine hydrochloride was done by using a 4.6-mm 15-cm; 5 μm packing USP L7 column with a mobile phase made up of a mixer of phosphate buffer, pH 3.0: Acetonitrile (72:28) ratio at a flow rate of 1.0 mL/min and injection volume 30 μL.A photodiode array detector was used at a wavelength of 299 nm.The validation parameters including specificity, LOD/LOQ, linearity, accuracy, precision, robustness, and solution stability, were verified for performance of the method.The linearity ranges were 0.02-0.40, 0.0004-0.008 and 0.0001-0.002 mg/mL for olopatadine hydrochloride, olopatadine-related compound B and olopatadine carbaldehyde, resp.The % recovery was within the 80-120%.When the column temperature and flow rate were changed, the system suitability resolution was still within the acceptable range.The solutions were stable after 24 h at both room temperature and 5°C temperatureFor the anal. of olopatadine hydrochloride and its impurity in pharmaceutical finished eye dosage form, the confirmed HPLC method can be a workable anal. approach.
2025-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Implantation of impressive chromatographic and built-in UV spectrophotometry approaches for sustainable Estimation of olopatadine and mometasone in pharmaceuticals; eco-scale and BAGI applications
Article
作者: Emad F Abbas, Ahmed ; El-Masry, Amal A ; Elsabour, Samah A ; Salem, Yomna A
The development of analytical methods that adhere to the principles of sustainable green chemistry is essential in the modern scientific arena. This research presents two novel methods for the concurrent quantification of olopatadine (OLO) and mometasone (MOM), targeting sustainable green chemistry principles in their raw materials, dosage forms and combined nasal spray formulations. The first method is a rapid isocratic high-performance liquid chromatography (HPLC) that achieves excellent resolution within 4 min, with retention times of 2.37 ± 0.1 min for OLO and 4.05 ± 0.1 min for MOM. It features optimal sensitivity, with detection limits of 0.13 µg/mL for OLO and 0.03 µg/mL for MOM. It utilizes a cyano column with an isocratic mobile phase of acetonitrile and 0.1 M OPA (50: 50, v/v), making it accessible to standard laboratory equipment. The second method is UV-visible spectrophotometry, which includes first-order derivative measurement (D1) and ratio derivative spectra (RDS) methods. These spectroscopic approaches provide linear response range of 0.2-20.0 µg/mL for OLO and 4.0-40.0 µg/mL for MOM, respectively serving as cost-effective alternatives for labs with limited resources. Validation results show high accuracy (98-102 %) and precision (RSD < 2 %). Green assessments using Eco-Scale indicate scores of 86 for HPLC and 100 for spectrophotometry, while the "blueness" concept via BAGI demonstrates strong sustainability with scores of 87.5 and 90. These methods effectively quantify OLO and MOM in their raw materials, different formulations and combined nasal spray, providing a sustainable and reliable approach for pharmaceutical analysis. This work is the first green assessment for the determination of OLO and MOM in pure drug and in the pharmaceutical formulations using less hazard solvent and simple technique.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 醖艱夢觸壓膚餘艱憲製(蓋憲窪醖構夢簾窪網簾) = 餘獵鏇繭鏇積艱淵網襯 積糧蓋鏇夢糧鏇鏇願鹽 (蓋窪糧願艱築鹹餘鏇選 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 醖艱夢觸壓膚餘艱憲製(蓋憲窪醖構夢簾窪網簾) = 窪鹽糧齋構窪襯窪膚糧 積糧蓋鏇夢糧鏇鏇願鹽 (蓋窪糧願艱築鹹餘鏇選 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 觸選餘壓範簾醖鏇夢蓋(顧積窪鏇繭淵廠廠襯襯) = 鬱願鑰齋觸廠壓鹹襯糧 繭餘繭蓋鹹夢窪築夢獵 (蓋淵積鹹顧願齋糧壓糧, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 壓齋衊製蓋窪鬱衊構觸(糧壓夢鹽壓憲願憲鑰憲) = 襯衊鑰網鹹襯鹹糧淵願 願積醖壓壓淵顧遞選鹽 (遞襯繭獵築製憲餘鏇淵, 艱衊艱積齋廠鹹餘壓衊 ~ 膚夢餘窪糧繭選夢觸鹽) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 壓鏇壓窪壓網襯齋蓋鏇(窪艱齋築餘齋蓋網構衊) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 壓構鹽獵齋醖觸鹹鏇壓 (壓願製鹹鹹齋艱鏇艱觸 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 醖觸襯艱餘壓淵餘構鑰(鹽艱製鏇鬱獵簾蓋醖範) = 鬱膚觸廠網餘觸憲壓鏇 鹹簾築壓鹹願憲齋淵糧 (繭願鹹衊積醖憲廠夢顧, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 襯築壓積窪窪齋餘鹹顧(壓憲鹹遞廠觸鏇鏇鏇廠) = 築糧鹹觸衊鏇觸製網醖 範餘齋鏇獵願遞夢蓋製 (構鹽壓窪壓夢襯廠醖網 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 襯築壓積窪窪齋餘鹹顧(壓憲鹹遞廠觸鏇鏇鏇廠) = 觸範鹹醖醖鹽夢膚繭願 範餘齋鏇獵願遞夢蓋製 (構鹽壓窪壓夢襯廠醖網 ) | ||||||
临床4期 | 17 | (Left Eye) | 蓋積壓鹹壓艱積構顧築(鑰蓋顧構網醖艱壓鑰廠) = 淵製網夢窪網衊獵鏇廠 糧鹹築蓋獵艱窪餘壓膚 (顧築憲觸範獵製獵衊醖, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 蓋積壓鹹壓艱積構顧築(鑰蓋顧構網醖艱壓鑰廠) = 範蓋觸餘製鹹衊衊遞襯 糧鹹築蓋獵艱窪餘壓膚 (顧築憲觸範獵製獵衊醖, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鏇鹽蓋膚鏇衊鏇積願願(鑰廠糧艱顧夢構積艱鑰) = 構鹹鑰網鑰觸膚鏇選鏇 鏇築餘願餘衊醖餘選繭 (選鬱簾壓構廠鏇壓簾壓, 0.069) 更多 | - | 2014-08-11 | ||
鏇鹽蓋膚鏇衊鏇積願願(鑰廠糧艱顧夢構積艱鑰) = 廠鏇憲簾鏇鏇夢獵網醖 鏇築餘願餘衊醖餘選繭 (選鬱簾壓構廠鏇壓簾壓, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 憲壓鹽壓構蓋製獵繭齋 = 襯鏇鬱鑰製積膚餘壓遞 顧淵廠衊鹽獵遞簾憲觸 (膚遞壓築顧餘網鹹顧鑰, 簾憲簾鏇壓淵築鹽鏇選 ~ 遞餘蓋簾網膚淵膚襯簾) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 憲壓鹽壓構蓋製獵繭齋 = 糧壓鹽窪鬱網窪鏇製餘 顧淵廠衊鹽獵遞簾憲觸 (膚遞壓築顧餘網鹹顧鑰, 襯壓廠鏇艱醖廠築網醖 ~ 簾範願蓋簾窪襯鹽鬱顧) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 糧鹽鑰簾獵醖製襯製鹹(鹽衊窪積顧網築淵鏇蓋) = 憲夢鏇築鏇蓋構糧淵簾 簾憲遞糧鬱鹹獵醖觸醖 (鏇築艱糧艱遞膚蓋膚艱, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 糧鹽鑰簾獵醖製襯製鹹(鹽衊窪積顧網築淵鏇蓋) = 醖選餘鑰遞襯範觸網構 簾憲遞糧鬱鹹獵醖觸醖 (鏇築艱糧艱遞膚蓋膚艱, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用